NCT05812807 2026-04-07
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
Clinical Trials
6 trialsNCT05601440 2026-03-27
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07447440 2026-03-11
RESOLBE
Clinica Universidad de Navarra, Universidad de Navarra
Recruiting
NCT06718010 2026-01-21
The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer
Fudan University
Recruiting
NCT03418961 2025-10-08
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06222957 2024-11-19
HEAT
Rigshospitalet, Denmark
Recruiting